Ustekinumab/Ustekinumab
Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-wo...
Gespeichert in:
| Veröffentlicht in: | Turkish Archives of Dermatology and Venereology 2022-04, Vol.56 (S1), p.48 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng ; tur |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | S1 |
| container_start_page | 48 |
| container_title | Turkish Archives of Dermatology and Venereology |
| container_volume | 56 |
| creator | Borlu, Murat |
| description | Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period. Keywords: Anti-IL-12/23, p40, ustekinumab Ustekinumab interlokin-12 (IL-12) ve IL-23'un ortak alt birimi p40'i hedef alan immunoglobulin G1 yapisinda bir monoklonal antikordur. Klinik arajtirmalarda PAJI75 yaniti saglanan hasta oranlari %66 ile 81 arasinda degijmektedir. Gercek yajam calijmalarinda ise uzun ilac sagkalim suresi ile one cikmaktadir. Vucut agirligina gore doz secimi yapildigi icin obez hastalarda kullanim kolayligi ve idame doneminde 12 haftada bir uygulanmasi ustekinumabin diger avantajlaridir. Anahtar Kelimeler: Anti-IL-12/23, p40, ustekinumab |
| doi_str_mv | 10.4274/turkderm.galenos.2022.63139 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A706129391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A706129391</galeid><sourcerecordid>A706129391</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1341-6c0bc190e82ec6ce4061669c3fa122cb156ea1c7d505dfa22b1cd65739da01fd3</originalsourceid><addsrcrecordid>eNqdkD9rwzAQxTW0kDTN3A-Q2YruTpaqMYT-g0CXBroF-SQFN7ENlvP9q9IOHTqVN9zx-N3jeEKsQEmNVq-ny3gKcezk0Z9jP2SJClEaAnJXYg4KXIWg32fiJucPpQw5Z-fibp-neGr7S-eb9a_9Vlwnf85x-TMXYv_48LZ9rnavTy_bza46AmmoDKuGwal4j5ENR60MGOOYkgdEbqA20QPbUKs6JI_YAAdTW3LBK0iBFmL1nfv19aHt0zCNnrs282FjSxg6clAo-QdVFGLX8tDH1Bb_PwdUCkIk-gSyiF9i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ustekinumab/Ustekinumab</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Borlu, Murat</creator><creatorcontrib>Borlu, Murat</creatorcontrib><description>Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period. Keywords: Anti-IL-12/23, p40, ustekinumab Ustekinumab interlokin-12 (IL-12) ve IL-23'un ortak alt birimi p40'i hedef alan immunoglobulin G1 yapisinda bir monoklonal antikordur. Klinik arajtirmalarda PAJI75 yaniti saglanan hasta oranlari %66 ile 81 arasinda degijmektedir. Gercek yajam calijmalarinda ise uzun ilac sagkalim suresi ile one cikmaktadir. Vucut agirligina gore doz secimi yapildigi icin obez hastalarda kullanim kolayligi ve idame doneminde 12 haftada bir uygulanmasi ustekinumabin diger avantajlaridir. Anahtar Kelimeler: Anti-IL-12/23, p40, ustekinumab</description><identifier>ISSN: 1019-214X</identifier><identifier>DOI: 10.4274/turkderm.galenos.2022.63139</identifier><language>eng ; tur</language><publisher>Galenos Yayinevi Tic. Ltd</publisher><subject>Antibodies ; Drug therapy ; Interleukins ; Monoclonal antibodies ; Patient compliance ; Psoriasis ; Viral antibodies</subject><ispartof>Turkish Archives of Dermatology and Venereology, 2022-04, Vol.56 (S1), p.48</ispartof><rights>COPYRIGHT 2022 Galenos Yayinevi Tic. Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Borlu, Murat</creatorcontrib><title>Ustekinumab/Ustekinumab</title><title>Turkish Archives of Dermatology and Venereology</title><description>Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period. Keywords: Anti-IL-12/23, p40, ustekinumab Ustekinumab interlokin-12 (IL-12) ve IL-23'un ortak alt birimi p40'i hedef alan immunoglobulin G1 yapisinda bir monoklonal antikordur. Klinik arajtirmalarda PAJI75 yaniti saglanan hasta oranlari %66 ile 81 arasinda degijmektedir. Gercek yajam calijmalarinda ise uzun ilac sagkalim suresi ile one cikmaktadir. Vucut agirligina gore doz secimi yapildigi icin obez hastalarda kullanim kolayligi ve idame doneminde 12 haftada bir uygulanmasi ustekinumabin diger avantajlaridir. Anahtar Kelimeler: Anti-IL-12/23, p40, ustekinumab</description><subject>Antibodies</subject><subject>Drug therapy</subject><subject>Interleukins</subject><subject>Monoclonal antibodies</subject><subject>Patient compliance</subject><subject>Psoriasis</subject><subject>Viral antibodies</subject><issn>1019-214X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqdkD9rwzAQxTW0kDTN3A-Q2YruTpaqMYT-g0CXBroF-SQFN7ENlvP9q9IOHTqVN9zx-N3jeEKsQEmNVq-ny3gKcezk0Z9jP2SJClEaAnJXYg4KXIWg32fiJucPpQw5Z-fibp-neGr7S-eb9a_9Vlwnf85x-TMXYv_48LZ9rnavTy_bza46AmmoDKuGwal4j5ENR60MGOOYkgdEbqA20QPbUKs6JI_YAAdTW3LBK0iBFmL1nfv19aHt0zCNnrs282FjSxg6clAo-QdVFGLX8tDH1Bb_PwdUCkIk-gSyiF9i</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Borlu, Murat</creator><general>Galenos Yayinevi Tic. Ltd</general><scope>IAO</scope></search><sort><creationdate>20220401</creationdate><title>Ustekinumab/Ustekinumab</title><author>Borlu, Murat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1341-6c0bc190e82ec6ce4061669c3fa122cb156ea1c7d505dfa22b1cd65739da01fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; tur</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Drug therapy</topic><topic>Interleukins</topic><topic>Monoclonal antibodies</topic><topic>Patient compliance</topic><topic>Psoriasis</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borlu, Murat</creatorcontrib><collection>Gale Academic OneFile</collection><jtitle>Turkish Archives of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borlu, Murat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ustekinumab/Ustekinumab</atitle><jtitle>Turkish Archives of Dermatology and Venereology</jtitle><date>2022-04-01</date><risdate>2022</risdate><volume>56</volume><issue>S1</issue><spage>48</spage><pages>48-</pages><issn>1019-214X</issn><abstract>Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted according to body weight and its administration every 12 weeks in the maintenance period. Keywords: Anti-IL-12/23, p40, ustekinumab Ustekinumab interlokin-12 (IL-12) ve IL-23'un ortak alt birimi p40'i hedef alan immunoglobulin G1 yapisinda bir monoklonal antikordur. Klinik arajtirmalarda PAJI75 yaniti saglanan hasta oranlari %66 ile 81 arasinda degijmektedir. Gercek yajam calijmalarinda ise uzun ilac sagkalim suresi ile one cikmaktadir. Vucut agirligina gore doz secimi yapildigi icin obez hastalarda kullanim kolayligi ve idame doneminde 12 haftada bir uygulanmasi ustekinumabin diger avantajlaridir. Anahtar Kelimeler: Anti-IL-12/23, p40, ustekinumab</abstract><pub>Galenos Yayinevi Tic. Ltd</pub><doi>10.4274/turkderm.galenos.2022.63139</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1019-214X |
| ispartof | Turkish Archives of Dermatology and Venereology, 2022-04, Vol.56 (S1), p.48 |
| issn | 1019-214X |
| language | eng ; tur |
| recordid | cdi_gale_infotracmisc_A706129391 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antibodies Drug therapy Interleukins Monoclonal antibodies Patient compliance Psoriasis Viral antibodies |
| title | Ustekinumab/Ustekinumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A06%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ustekinumab/Ustekinumab&rft.jtitle=Turkish%20Archives%20of%20Dermatology%20and%20Venereology&rft.au=Borlu,%20Murat&rft.date=2022-04-01&rft.volume=56&rft.issue=S1&rft.spage=48&rft.pages=48-&rft.issn=1019-214X&rft_id=info:doi/10.4274/turkderm.galenos.2022.63139&rft_dat=%3Cgale%3EA706129391%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A706129391&rfr_iscdi=true |